Tigderimus
Alternative Names: IMM 125; Oxeclosporin; SDZ IMM 125Latest Information Update: 09 Aug 2002
At a glance
- Originator Novartis
- Class Antiasthmatics; Antineoplastics
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Cancer
- Discontinued Psoriasis; Rheumatoid arthritis; Transplant rejection